Grail bets big on flagship cancer test after spin-off from Illumina
CHICAGO, June 24 (Reuters) – U.S. cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina, is betting that commercial partnerships with health systems, employers and life insurance companies of its flagship cancer-detection test will power its near-term growth as an independent company. The … Read more